Krystal Biotech, Inc. (KRYS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $321.42
- As of
Kresmion compiles this page from KRYS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Krystal Biotech, Inc. (KRYS): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-15.
See the full KRYS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for KRYS on one page. Preview it with sample data, then open it live with a free account.
Preview the KRYS dossierActive events for KRYS
- high13F: funds added
7 tracked funds increased KRYS this 2026Q2, institutional consensus
- highInsider cluster: sales
2 insiders at KRYS sold $18.0M this week
- high13F: large increase
CITADEL ADVISORS LLC added +790% to KRYS (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +522% to KRYS (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +2581% to KRYS (2026Q2)
FREE, NO ACCOUNT
Every event on KRYS, as it fires
You are seeing 5 of 16 events recorded on KRYS since 2026-06-09.
The five above landed across 3 days. The other 11 were recorded on 3 other days. 9 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KRYS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 501147102 · 2026Q2 | $22.2M | 0.03% | , |
| Bridgewater Associates, LPCUSIP 501147102 · 2026Q2 | $20.3M | 0.08% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 501147102 · 2026Q2 | $2.3M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 501147102 · 2026Q2 | $1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KRYS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
KRYS against its peers
KRYS's operating margin of 41.5% ranks in the 97th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | KRYS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 389M USD | 266M USD | 55 | 18 |
| Gross margin | n/a | 84.8% | n/a | 8 |
| Operating margin | 41.5% | -72.3% | 97 | 16 |
| Net margin | 52.6% | -93.2% | 91 | 16 |
| Return on equity | 16.8% | -21.7% | 93 | 19 |
| P / E | 47.0x | n/a | n/a | 4 |
Peers (23): PCVX, IBRX, SYRE, NUVL.D, PTGX, MDGL, CAI, CRNX.D, KYMR, APGE.D, TGTX, CYTK, ARWR, BMRN, PRAX, ABVX, ALKS, IONS, SMMT, GRAL, IOVA, BBIO, LGND. Left out: SBMFF (no annual filing), BCHMY (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (KRYS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow KRYS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to KRYS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.